\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\:\\ tenderness\\ to\\ palpation\\ of\\ right\\ upper\\ arm\\.\\ active\\ elbow\\ flexion\\ and\\ extension\\ limited\\ by\\ pain\\ in\\ upper\\ arm\\.\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ laboratory\\ data\\:\\ anemia\\,\\ hypercalcemia\\,\\ azotemia\\,\\ spep\\ m\\ spike\\,\\ peripheral\\ blood\\ smear\\ shows\\ rouleux\\ formation\\,\\ bm\\ aspirate\\ with\\ plasmacytosis\\ \\(60\\%\\)\\.\ \(0\)\
\-\ treatment\\ usually\\ consists\\ of\\ chemotherapy\\ with\\ alkylating\\ agents\\ and\\ induces\\ remission\\ in\\ 50\\ to\\ 70\\ percent\\ of\\ patients\\.\\ \\ however\\,\\ median\\ survival\\ is\\ 3\\ years\\.\\ those\\ with\\ multiple\\ lesions\\ rarely\\ survive\\ longer\\ than\\ a\\ year\\.\\ \\ new\\ therapies\\ include\\ peripheral\\ stem\\ cell\\ transplants\\ in\\ combination\\ with\\ the\\ traditional\\ chemotherapy\\ regimen\\.\\ this\\ combined\\ therapy\\ has\\ induced\\ remission\\ in\\ 50\\ percent\\ of\\ patients\\.\\ \\ complications\\ such\\ as\\ recurrent\\ infections\\,\\ pathologic\\ fractures\\,\\ and\\ renal\\ failure\\ are\\ common\\.\ \(0\)\
\-\ lateral\\ radiograph\\ of\\ the\\ humerus\\ shows\\ extensive\\ lytic\\ lesions\\ of\\ the\\ medullary\\ canal\\ with\\ endosteal\\ scalloping\\ \\ consistent\\ with\\ multiple\\ myeloma\\.\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ lateral\\ radiograph\\ of\\ the\\ skull\\ shows\\ small\\ lytic\\ lesions\\ in\\ the\\ frontal\\ region\\ consistent\\ with\\ multiple\\ myeloma\\.\ \(0\)\
\-\ multiple\\ myeloma\ \(25\)\
\-\ multiple\\ myeloma\\,\\ metastatic\\ cancer\\,\\ mgus\ \(0\)\
\-\ 64\\ yo\\ wm\\ with\\ right\\ arm\\/shoulder\\ pain\\ that\\ worsens\\ with\\ movement\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ myeloma\\:\\ 0\\.10398682350275268\ \(0\)\
\-\ remission\\:\\ 0\\.06327675080342113\ \(0\)\
\-\ percent\\:\\ 0\\.04876057948279399\ \(0\)\
\-\ multiple\\:\\ 0\\.04711534040521646\ \(0\)\
\-\ azotemia\\:\\ 0\\.04615454672233769\ \(0\)\
\-\ rouleux\\:\\ 0\\.04615454672233769\ \(0\)\
\-\ plasmacytosis\\:\\ 0\\.04615454672233769\ \(0\)\
\-\ alkylating\\:\\ 0\\.04615454672233769\ \(0\)\
\-\ mgus\\:\\ 0\\.04615454672233769\ \(0\)\
\-\ arm\\/shoulder\\:\\ 0\\.042525503892180905\ \(0\)\
\-\ lytic\\:\\ 0\\.04005325483966243\ \(0\)\
\-\ induces\\:\\ 0\\.037728170217447114\ \(0\)\
\-\ arm\\:\\ 0\\.03747724043074921\ \(0\)\
\-\ shows\\:\\ 0\\.036901157587364584\ \(0\)\
\-\ spep\\:\\ 0\\.03677360709287143\ \(0\)\
\-\ spike\\:\\ 0\\.03677360709287143\ \(0\)\
\-\ lesions\\:\\ 0\\.035930269733151006\ \(0\)\
\-\ bm\\:\\ 0\\.03526741823186735\ \(0\)\
\-\ transplants\\:\\ 0\\.03526741823186735\ \(0\)\
\-\ survive\\:\\ 0\\.034650753123718736\ \(0\)\
\-\ 50\\:\\ 0\\.034041864048626226\ \(0\)\
\-\ worsens\\:\\ 0\\.03360012121030433\ \(0\)\
\-\ traditional\\:\\ 0\\.03272549249479038\ \(0\)\
\-\ peripheral\\:\\ 0\\.032376265151980284\ \(0\)\
\-\ smear\\:\\ 0\\.03233749264058241\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.03207273073445932\ \(0\)\
\-\ aspirate\\:\\ 0\\.031638375401710564\ \(0\)\
\-\ hypercalcemia\\:\\ 0\\.029971078380147554\ \(0\)\
\-\ therapies\\:\\ 0\\.029971078380147554\ \(0\)\
\-\ endosteal\\:\\ 0\\.028708449810425626\ \(0\)\
\-\ radiograph\\:\\ 0\\.028502080145773434\ \(0\)\
\-\ wm\\:\\ 0\\.028347230587980853\ \(0\)\
\-\ regimen\\:\\ 0\\.028009332571553778\ \(0\)\
\-\ scalloping\\:\\ 0\\.02754015896584861\ \(0\)\
\-\ induced\\:\\ 0\\.026841041726976763\ \(0\)\
\-\ stem\\:\\ 0\\.02658559584127293\ \(0\)\
\-\ agents\\:\\ 0\\.026224376618828163\ \(0\)\
\-\ median\\:\\ 0\\.02588647860240109\ \(0\)\
\-\ longer\\:\\ 0\\.02526981349425248\ \(0\)\
\-\ combined\\:\\ 0\\.024718187757824073\ \(0\)\
\-\ consists\\:\\ 0\\.024546513292782235\ \(0\)\
\-\ 64\\:\\ 0\\.024380289741396995\ \(0\)\
\-\ data\\:\\ 0\\.024219181580838075\ \(0\)\
\-\ survival\\:\\ 0\\.023986449839629522\ \(0\)\
\-\ patients\\:\\ 0\\.023157849208021216\ \(0\)\
\-\ elbow\\:\\ 0\\.023082718202629558\ \(0\)\
\-\ m\\:\\ 0\\.023082718202629558\ \(0\)\
\-\ humerus\\:\\ 0\\.023019255582041362\ \(0\)\
\-\ combination\\:\\ 0\\.022537481243191878\ \(0\)\
\-\ movement\\:\\ 0\\.022367663045531387\ \(0\)\
\-\ anemia\\:\\ 0\\.022257435772244306\ \(0\)\
\-\ consistent\\:\\ 0\\.0219402960087037\ \(0\)\
\-\ upper\\:\\ 0\\.021592466024803334\ \(0\)\
\-\ 70\\:\\ 0\\.02149732053745636\ \(0\)\
\-\ medullary\\:\\ 0\\.02149732053745636\ \(0\)\
\-\ rarely\\:\\ 0\\.02145036415011206\ \(0\)\
\-\ infections\\:\\ 0\\.021266639962618503\ \(0\)\
\-\ flexion\\:\\ 0\\.020590138750681296\ \(0\)\
\-\ those\\:\\ 0\\.020357407009472743\ \(0\)\
\-\ pe\\:\\ 0\\.020098349118041488\ \(0\)\
\-\ pathologic\\:\\ 0\\.0195829560666632\ \(0\)\
\-\ 60\\:\\ 0\\.01951791669494301\ \(0\)\
\-\ lateral\\:\\ 0\\.019336838174079062\ \(0\)\
\-\ skull\\:\\ 0\\.019054286342369997\ \(0\)\
\-\ limited\\:\\ 0\\.0188797501106025\ \(0\)\
\-\ recurrent\\:\\ 0\\.0188797501106025\ \(0\)\
\-\ formation\\:\\ 0\\.018467284781528603\ \(0\)\
\-\ extensive\\:\\ 0\\.017891914777218562\ \(0\)\
\-\ canal\\:\\ 0\\.01777478232824195\ \(0\)\
\-\ complications\\:\\ 0\\.01772865337702648\ \(0\)\
\-\ failure\\:\\ 0\\.017525959595975745\ \(0\)\
\-\ active\\:\\ 0\\.017081459890287334\ \(0\)\
\-\ fractures\\:\\ 0\\.016941301560106158\ \(0\)\
\-\ laboratory\\:\\ 0\\.016487391287194064\ \(0\)\
\-\ extension\\:\\ 0\\.01597030011089871\ \(0\)\
\-\ new\\:\\ 0\\.015590512967542191\ \(0\)\
\-\ palpation\\:\\ 0\\.014931618221717551\ \(0\)\
\-\ cancer\\:\\ 0\\.014707671541176782\ \(0\)\
\-\ \\,\\:\\ 0\\.014173301859543842\ \(0\)\
\-\ frontal\\:\\ 0\\.014053884473734856\ \(0\)\
\-\ such\\:\\ 0\\.013986035548904987\ \(0\)\
\-\ tenderness\\:\\ 0\\.0136068708004274\ \(0\)\
\-\ usually\\:\\ 0\\.013586011800349525\ \(0\)\
\-\ yo\\:\\ 0\\.01346257342043331\ \(0\)\
\-\ renal\\:\\ 0\\.013442280363654814\ \(0\)\
\-\ years\\:\\ 0\\.013137398623133416\ \(0\)\
\-\ region\\:\\ 0\\.012636655639996401\ \(0\)\
\-\ include\\:\\ 0\\.012550541822148098\ \(0\)\
\-\ however\\:\\ 0\\.012457424374853773\ \(0\)\
\-\ blood\\:\\ 0\\.012211576295860208\ \(0\)\
\-\ cell\\:\\ 0\\.012085029903567992\ \(0\)\
\-\ therapy\\:\\ 0\\.011961470137385409\ \(0\)\
\-\ \\:\\:\\ 0\\.011835338387336808\ \(0\)\
\-\ than\\:\\ 0\\.011722768873917665\ \(0\)\
\-\ common\\:\\ 0\\.011708205298201033\ \(0\)\
\-\ metastatic\\:\\ 0\\.011262352898513562\ \(0\)\
\-\ in\\:\\ 0\\.011031341103148035\ \(0\)\
\-\ pain\\:\\ 0\\.010927834214981516\ \(0\)\
\-\ 3\\:\\ 0\\.010476311658149422\ \(0\)\
\-\ \\%\\:\\ 0\\.010436235776680668\ \(0\)\
\-\ small\\:\\ 0\\.010306676881576538\ \(0\)\
\-\ right\\:\\ 0\\.009441169728904887\ \(0\)\
\-\ treatment\\:\\ 0\\.009055586175920874\ \(0\)\
\-\ has\\:\\ 0\\.008401570526148053\ \(0\)\
\-\ that\\:\\ 0\\.007727647793501693\ \(0\)\
\-\ by\\:\\ 0\\.007449585880863219\ \(0\)\
\-\ as\\:\\ 0\\.006767421496827895\ \(0\)\
\-\ are\\:\\ 0\\.006098816086542418\ \(0\)\
\-\ with\\:\\ 0\\.0055132857843403545\ \(0\)\
\-\ this\\:\\ 0\\.005032132006880278\ \(0\)\
\-\ year\\:\\ 0\\.005005786750119973\ \(0\)\
\-\ to\\:\\ 0\\.004471917365895145\ \(0\)\
\-\ of\\:\\ 0\\.004269772804114759\ \(0\)\
\-\ \\(\\:\\ 0\\.003781998566721783\ \(0\)\
\-\ \\)\\:\\ 0\\.0037357994351481945\ \(0\)\
\-\ the\\:\\ 0\\.003619091222608005\ \(0\)\
\-\ is\\:\\ 0\\.0029439307768833805\ \(0\)\
\-\ and\\:\\ 0\\.0028273665821814415\ \(0\)\
\-\ \\.\\:\\ 0\\.002230337346430132\ \(0\)\
\-\ a\\:\\ 0\\.00207643875297697\ \(0\)\
